Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Abstract Background More than 2.7 million hospitalizations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the coronavirus in 2020. Interventions against SARS-CoV-2 are still in high need to prevent admissions to ICUs worldwide. FX06, a naturally occurring peptide i...

Full description

Bibliographic Details
Main Authors: Jan Kloka, Benjamin Friedrichson, Stephanie Dauth, Ann Christina Foldenauer, Anita Bulczak-Schadendorf, Maria J. G. T. Vehreschild, Francisco Maio Matos, Antoni Riera-Mestre, Antoinette D. I. van Asselt, Edoardo De Robertis, Vilma Traskaite Juskeviciene, Patrick Meybohm, Dana Tomescu, Karine Lacombe, Coen D. A. Stehouwer, Kai Zacharowski, on behalf of the IXION Collaboration Group
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
FX06
COVID-19
Disease progression
Capillary leak
Inflammation
Online Access:https://doi.org/10.1186/s13063-022-06609-x

Internet

https://doi.org/10.1186/s13063-022-06609-x

Similar Items